FDA approval of EKTERLY makes KalVista Pharmaceuticals, Inc. the first to offer an oral on-demand HAE therapy. Click here to find out why KALV is a Strong Buy.

The Food and Drug Administration (FDA) has approved Ekterly ® (sebetralstat) for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged 12 years and older.

Ekterly becomes the first FDA-approved oral on-demand treatment for hereditary angioedema in patients aged 12 years and older ...

Under the new leadership of Marty Makary, the FDA should focus more attention on the critical role of real-world clinical data — such as from health insurance databases — in the ongoing assessment of ...

Another Rock Island County Sheriff’s Office deputy said he intends to run for sheriff in 2026. Timothy Gillette, a 28-year ...

Despite the many warnings by law enforcement — reinforced by this newspaper — to be wary of anyone purporting to act in your best interests, egregious examples of violations of that trust continue ...

After delaying a June PDUFA date, the U.S. FDA has approved Kalvista Pharmaceuticals Inc.’s Ekterly (sebetralstat) for hereditary angioedema (HAE) in those aged 12 and older. The plasma kallikrein ...

Ekterly comes in the form of a 300 mg tablet. The recommended dosage is 600 mg split into two doses taken at the earliest sign of an attack, according to the prescribing information. Additional ...

The company had blamed FDA "resource constraints" for the delay, while a rival drug for hereditary angioedema received an ...

EKTERLY is an FDA-approved oral therapy for the on-demand treatment of hereditary angioedema (HAE) ELK GROVE VILLAGE, Ill., ...

KalVista Pharmaceuticals said on Monday the U.S. Food and Drug Administration has approved its drug, the first on-demand oral ...